HARTFORD, Conn., Sept. 2 /PRNewswire/ -- Shepherd, Finkelman, Miller & Shah, LLC (http://www.classactioncounsel.com/; e-mail: ), a law firm with offices in Connecticut, Pennsylvania, New Jersey and Florida, announces that it has filed a lawsuit seeking class action status in the United States District Court for the Northern District of Georgia on behalf of all persons (the "Class") who purchased the securities of Immucor, Inc. (NASDAQ:BLUDE) ("Immucor" or the "Company") during the period January 7, 2005 and August 29, 2005 (the "Class Period"). Also named as Defendants are Dr. Gioacchino De Chirico, Steven C. Ramsey, and Edward L. Gallup. A copy of the Complaint may be obtained from the Court, or you can call our offices toll free at either 866/540-5505 or 877/891-9880 to speak with an attorney regarding this matter and we will send you a copy of the Complaint. The Complaint alleges that the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), and Rule 10b-5 promulgated thereunder. During the Class Period, the complaint claims that Defendants misrepresented that Immucor's financial statements and disclosures fairly and accurately reflected the Company's results of operations as required by Generally Accepted Accounting Principles ("GAAP") and the Exchange Act. The Complaint further charges that Defendants' Sarbanes-Oxley certifications during the Class Period were also false and misleading, as the Company, knowingly or with severe recklessness, lacked adequate internal controls and failed to keep proper books and records, in violation of its well-publicized Code of Corporate Conduct. The nature of Defendants' fraud began to come to light on August 26, 2005, when the Company was forced to announce that the Securities and Exchange Commission (the "SEC") had launched a formal investigation into payments made by its Italian unit and its President, Defendant De Chirico, in October 2003 to a physician connected with a hospital with which the Company was doing business. After the market closed on August 29, 2005, the Company revealed further that its Chief Financial Officer had resigned, that it would be revising its previously-issued results for at least two quarters in order to account for a previously unrecorded accrued bonus, and that its Form 10-K for fiscal year 2005 would be further delayed due to additional accounting and auditing procedures the Company claimed were necessary to properly reflect the accrued bonus and to render the internal controls report required by Section 404 of Sarbanes-Oxley. In response to this news, the price of the Company's common stock dropped from a closing price of $28.61 on August 25, 2005 before the market learned of the SEC's formal investigation to close at $24.00 per share on August 30, 2005. A staggering 6 million shares of Immucor common stock were traded on August 30, 2005 alone. This volume is nearly ten times the average daily volume. During the first six months of 2005, Immucor insiders sold approximately 186,000 shares, for proceeds of about $4,970,000 million. During this time, Defendants led the market to believe that the internal control issue involving the Italian subsidiary was "an isolated event" that was not expected to lead to more than a $350,000 fine and increased investigation expenses that had already been factored into the Company's bottom line. In fact, however, the opposite was true. Immucor's internal control problems, as the market later learned, were not confined to its Italian subsidiary and did not center solely around this alleged "isolated event." If you purchased Immucor securities between January 7, 2005 and August 29, 2005 (inclusive), you may qualify to serve as lead plaintiff on behalf of the Class. All motions for appointment as lead plaintiff must be filed with the Court no later than October 31, 2005. Any member of the proposed Class may move the Court to serve as lead plaintiff in this action through counsel of his or her choice, or may remain an absent class member. There are certain legal requirements to serve as lead plaintiff, which we would be pleased to discuss with you. Please contact James E. Miller, Esquire (866/540-5505; ), or James C. Shah, Esquire (877/891-9880; ), if you would like to discuss this action or have any question regarding this notice or your rights. Shepherd, Finkelman, Miller & Shah, LLC (http://www.classactioncounsel.com/) is a national law firm that represents investors, including institutions and individuals, as well as consumers, in class action and other complex litigation, and maintains offices in Connecticut, Florida, New Jersey and Pennsylvania. The firm's attorneys have appeared in matters on behalf of our clients throughout the United States and have been appointed lead counsel in a number of class actions and corporate governance matters. DATASOURCE: Shepherd, Finkelman, Miller & Shah, LLC CONTACT: James E. Miller, Esquire, +1-866-540-5505, , or James C. Shah, Esquire, +1-877-891-9880; , both of Shepherd, Finkelman, Miller & Shah, LLC Web site: http://www.classactioncounsel.com/

Copyright